{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:46:54Z","timestamp":1793710014091,"version":"4.6.1"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,3,29]],"date-time":"2009-03-29T00:00:00Z","timestamp":1238284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Hairy cell leukaemia (HCL) was first described 50\u2003years ago. Median survival was then 4\u2003years. The purine analogues, introduced in the 1980s, transformed this prognosis. We reviewed data retrospectively from 233 patients, treated with pentostatin (<jats:italic>n<\/jats:italic>\u2003=\u2003188) or cladribine (<jats:italic>n<\/jats:italic>\u2003=\u200345), to investigate the current long\u2010term outlook. Median follow\u2010up was 16\u2003years. There were no significant differences in outcome between the two agents. Overall, the complete response (CR) rate was 80% and median relapse\u2010free survival was 16\u2003years. After relapse (<jats:italic>n<\/jats:italic>\u2003=\u200379) or non\u2010response (<jats:italic>n<\/jats:italic>\u2003=\u20035), 26 patients received pentostatin and 58 cladribine; 69% achieved CR and median relapse\u2010free survival was 11\u2003years. After third\u2010line therapy (<jats:italic>n<\/jats:italic>\u2003=\u200323), 50% achieved CR and median relapse\u2010free survival was 6\u00b75\u2003years. However, CRs were equally durable, whether after first, second or third\u2010line therapy. Complete responders and those with both haemoglobin &gt;100\u2003g\/l and platelet count &gt;100\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/l before treatment had the longest relapse\u2010free survival (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001). Patients still in CR at 5\u2003years had only a 25% risk of relapse by 15\u2003years. Outcomes for patients with recurrent disease improved with the monoclonal antibody rituximab, combined with either purine analogue. Overall only eight patients died of HCL\u2010related causes. Patients achieving a CR can expect a normal lifespan.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2009.07668.x","type":"journal-article","created":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T17:48:45Z","timestamp":1238435325000},"page":"733-740","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["Long\u2010term follow\u2010up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16\u2003years from diagnosis"],"prefix":"10.1111","volume":"145","author":[{"given":"Monica","family":"Else","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Dearden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estella","family":"Matutes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garcia\u2010Talavera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ama Z. S.","family":"Rohatiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve A. N.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel T. J.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnenna","family":"Osuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Forconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Catovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,6,2]]},"reference":[{"key":"e_1_2_7_2_1","article-title":"Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia","volume":"1","author":"Anonymous","year":"1987","journal-title":"Leukemia"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V13.7.609.609"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0308-2261(21)00561-0","article-title":"Hairy cell leukaemia and prolymphocytic leukaemia","volume":"6","author":"Catovsky D.","year":"1977","journal-title":"Clinics in Haematology"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07333.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0173"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.3007"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-006-0055-z"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21447"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23032"},{"key":"e_1_2_7_12_1","first-page":"2981","article-title":"Long\u2010term follow\u2010up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin","volume":"96","author":"Flinn I.W.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_7_13_1","first-page":"188","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Foucar K.","year":"2008"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-89-5-677"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.093"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.974"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403418"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.7.1523"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402784"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.5041045.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199004193221605"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<352::AID-CNCR15>3.0.CO;2-8"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4590"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.6.1918"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.12.1336"},{"key":"e_1_2_7_26_1","unstructured":"UK Statistics Authority(2008a) Death rates per 1 000 population by sex and age: 1998\u20132000 (http:\/\/www.statistics.gov.uk\/StatBase\/xsdataset.asp?vlnk=3728&Pos=1&ColRank=1&Rank=176) & 2001\u20132003 (http:\/\/www.statistics.gov.uk\/StatBase\/ssdataset.asp?vlnk=8262&Pos=6&ColRank=1&Rank=208). Accessed 17 November 2008."},{"key":"e_1_2_7_27_1","unstructured":"UK Statistics Authority(2008b) Cancer Statistics Registrations series MB1 no.36.http:\/\/www.statistics.gov.uk\/StatBase\/Product.asp?vlnk=8843&Pos=&ColRank=1&Rank=272. Accessed 17 November."}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2009.07668.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2009.07668.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:03:16Z","timestamp":1697410996000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2009.07668.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1365-2141.2009.07668.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07668.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"2009-06-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}